Vipoglanstat
Small moleculeexperimental
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 4, 2019 (NCT04036227)
Timeline
Indications
Mechanism of action
- Prostaglandin E synthaseINHIBITOR
PTGES inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
Cn1c(Nc2c(Cl)ccc(CNC(=O)C(C)(C)C)c2Cl)nc2cc(C(=O)N[C@H]3CC[C@H](C(F)(F)F)CC3)c(OCC(F)F)cc21- Mol. weight
- 678.53 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3694493 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04744207 | Phase 2 | Dec 29, 2020 | Ergomed, Gesynta Pharma AB |
| NCT04617509 | Phase 1 | Mar 31, 2020 | Clinical Trial Consultants AB, Gesynta Pharma AB, RISE Research Institutes of Sweden AB |
| NCT04036227 | Phase 1 | Jul 4, 2019 | Clinical Trial Consultants AB, Gesynta Pharma AB |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gesynta Pharma AB | For profit | 3 | 3 | 2 | 2019 |
| Clinical Trial Consultants AB | For profit | 2 | 0 | 1 | 2019 |
| Ergomed | For profit | 1 | 0 | 1 | 2020 |
| RISE Research Institutes of Sweden AB | Academic/Hospital | 1 | 0 | 1 | 2020 |
4 organizations
Page 1 / 1